Prognostic relevance of serum levels of the angiogenic peptide bFGF in advanced carcinoma of the head and neck treated by primary radiochemotherapy

Head and Neck

Volumn 22, Issue 7, 2000, Pages 666-673

  Dietz, Andreas ^a   Rudat, Volker ^a   Conradt, Christian ^a   Weidauer, Hagen ^a   Ho, Antony ^a   Moehler, Thomas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Angiogenesis; bFGF; Head and neck cancer; MMP 2; Radiochemotherapy; VEGF

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; ENDOTHELIAL CELL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; LYMPHOKINE; TUMOR MARKER; VASCULOTROPIN; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; HEAD AND NECK TUMOR; HUMAN; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; ENDOTHELIAL GROWTH FACTORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTOR 2; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHOKINES; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034292860     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0347(200010)22:7<666::AID-HED5>3.0.CO;2-9     Document Type: Article

References (31)

1. Andl T, Kahn T, Pfuhl A, et al. Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res 1998;58(1):5-13.
2. Erber R, Conradt C, Homann N, et al. TP53 DNA Contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene 1998;16:1671-1679.
3. Wenz F, Lohr F, Flentje M, Rudat V, Dietz A, Wannenmacher M. Predictive value of the flow cytometric PCNA assay (proliferating cell nuclear antigen) in head and neck tumors after accelerated hyperfractionated radiochemotherapy. Int J Radiat Oncol Biol Phys 1997;37(4): 771-776.
4. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995;1:27-31.
5. Risau W. Mechanisms of angiogenesis. Nature 1997; 386(17):671-674.
6. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-1887.
7. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
8. Skobe M, Rockwell P, Goldstein N, Vossler S, Fusenig NE. Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 1997;3:1222-1227.
9. Brooks PC, Strömblad S, Sanders LC, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha-v-beta-3. Cell 1996;85(5):683-693.
10. Kawamata H, Uchida D, Hamano H, et al. Active-MMP2 in cancer cell nests of oral cancer patients: correlation with lymph node metastasis. Int J Oncol 1998; 13(4): 699-704.
11. Delorme S, Dietz A, Rudat V, Zuna I, Bahner ML, van Kaick G. Prognostic significance of color Doppler findings in head and neck tumors. Ultrasound in Med Biol 1997;23(9):1311-1317.
12. Dirix LY, Vermeulen PB, Hubens G, et al. Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann Oncol 1996;7(8):843-848.
13. Meyer G, Yu E, Siegal J, Petteway J, Blumenstein B, Brawer M. Serum basic fibroblast growth factor in men with and without prostate carcinoma. Cancer 1995;76: 2304-2311.
14. Landriscina M, Casano A, Ratto C, et al. Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. Br J Cancer 1998;78(6):765-770.
15. Brattstrom D, Bergqvist M, Larsson A, et al. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients. Anticancer Res 1998;18:1123-1128.
16. Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 1997;90:3167-3172.
17. Petruzzelli GJ, Benefield J, Taitz AD, et al. Heparin-binding growth factor(s) derived from head and neck squamous cell carcinomas induce endothelial cell proliferations. Head Neck 1997;19(7):576-582.
18. Dellacono FR, Spiro J, Eisma R, Kreutzer D. Expression of basic fibroblast growth factor and its receptors by head and neck squamous carcinoma tumor and vascular endothelial cells. Am J Surg 1997;174(5):540-544.
19. Rudat V, Dietz A, Schramm O, Maier H, Flentje M, Wannenmacher M. Prognostic impact of the tumor volume on the outcome of patients with advanced head and neck cancer after concomitant boost radiochemotherapy. Radiotherapy Oncology 1999;(in press).
20. Zmering MB, Brandhi ML, DeGrange DA, et al. Circulating fibroblast growth factor-like substance in familial multiple endocrine neoplasia type 1. J Clin Endocrin Metab 1990;70:149-154.
21. Sliutz G, Tempfer C, Obermair A, Reinthaller A, Gitsch G, Keinz C. Serum evaluation of basic fibroblast growth factor in cervical cancer patients. Cancer Lett 1995;94: 227-231.
22. Sliutz G, Tempfer C, Obermair A, Dadak C, Kainz C. Serum evaluation of basic FGF in breast cancer patients. Anticancer Res 1995;15:2675-2678.
23. Klijanienko-J, el-Naggar AK, de-Braud F, et al. Tumor vascularizatoin, mitotic index, histopathologic grade and DANN ploidy in the assessment of 114 head and neck squamous cell carcinomas. Cancer 1995;75:1649-1656.
24. Mauceri HJ, Hanna NN, Beckett MA, et al. Combined effects of angiostatin and ionizing radiation in tumor therapy. Nature 1998;394:287-291.
25. Gradishar WJ. An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action. Invest New Drugs 1997;15:49-59.
26. Brooks PC, Stromblad S, Klemke R, Vischer D, Sarkar FH, Cheresh DA. Antiintegrin alpha-v-beta-3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995;96(4):1815-1822.
27. Wang Y, Becker D. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med 1997;3:887-893.
28. Salven P, Heikkila P. Anttonen A, Kajanti M, Joensuu H. Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance. Mod Pathol 1997;10:1128-1133.
29. Bramhall SR, Neoptolemos JP, Stamp GW, Lemoine NR. Imbalance of expression of matrix metalloproteinase (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol 1997;182(3):347-355.
30. Mori M, Mimori K, Shiraishi T, et al. Analysis of MT1-MMP and MMP2 expression in human gastric cancers. Int J Cancer 1997;74(3):316-321.
31. Musso O, Theret N, Campion JP, et al. In situ detection of matrix metalloproteinase-2 (MMP2) and the metalloproteinase inhibitor TIMP2 transcripts in human primary hepatocellular carcinoma and in liver metastases. J Hepatol 1997;26(3):593-605.